1. What Evergreening Means in Patent Practice
Evergreening occurs when a patent holder files successive applications claiming small, incremental modifications to an existing patented product, with the goal of maintaining market exclusivity beyond the original patent term. The strategy is common in pharmaceuticals, where a company might file new patents on a new formulation, dosage, or delivery mechanism of a drug nearing patent expiration. In software and technology, similar tactics involve patenting minor interface changes or algorithmic refinements. From a practitioner's perspective, the line between legitimate patent prosecution and anticompetitive evergreening is where most disputes arise.
The Patent Office Examination Process
When a company files successive patent applications, the U.S. Patent and Trademark Office (USPTO) examines each application on its merits. Examiners assess whether each claimed invention meets the statutory requirements of novelty, non-obviousness, and utility under 35 U.S.C. § 101 and § 103. The examiner may cite prior art, including the applicant's own earlier patents, to reject claims that appear obvious in light of existing disclosures. Many evergreening applications face rejection on obviousness grounds, yet some proceed to issuance because the improvements, however modest, satisfy the statutory threshold. This creates a paradox: a patent can be legally valid even if its commercial purpose is to extend exclusivity rather than to advance the state of the art.
Why Courts Scrutinize the Strategy
Federal courts have grown skeptical of aggressive evergreening tactics, particularly when combined with other exclusionary conduct. In cases involving technology patent law disputes, judges examine whether the patent holder is using valid patents as a shield or as a sword to prevent competition. The concern is that a series of overlapping patents can create an artificial "patent thicket" that blocks competitors from entering the market, even after the original patent expires. Courts look to the strength of the underlying inventions and whether the patent holder is pursuing a legitimate licensing strategy or an anticompetitive scheme.
2. Regulatory and Antitrust Challenges
The Federal Trade Commission (FTC) and the Department of Justice (DOJ) have brought enforcement actions against companies accused of using evergreening as an anticompetitive tactic. The agencies do not object to valid patents, but they scrutinize conduct that leverages patent rights to delay generic or competitive entry beyond what the patent law itself permits. In pharmaceutical cases, regulators focus on whether the company is filing sham continuation applications or manipulating the FDA approval process to delay generic competitors. Antitrust liability typically requires evidence that the patent holder engaged in conduct outside the scope of the patent grant itself.
The Ftc's Approach to Pharmaceutical Patents
The FTC has challenged evergreening in several high-profile cases, arguing that successive patent filings, combined with aggressive enforcement and reverse-settlement agreements with generic manufacturers, constitute anticompetitive conduct. The agency scrutinizes whether the improvements claimed in successive patents would have been obvious to a person skilled in the art. When the FTC brings a case, it often argues that the patent holder is using the patent system not to protect genuine innovation but to suppress competition. These cases are rarely as clean as the statute suggests; outcomes depend heavily on the specific facts and the judge's view of patent policy.
New York Courts and Patent Litigation
Patent disputes involving New York parties or contracts often proceed in the U.S. District Court for the Southern District of New York (SDNY), which has developed significant expertise in patent cases. SDNY judges apply Federal Circuit precedent on patent validity and infringement but often apply New York contract law to licensing disputes. The court has been receptive to antitrust defenses against patent enforcement, particularly where the patent holder is accused of leveraging patents to maintain monopoly power. Practitioners litigating evergreening cases in SDNY must anticipate both patent-validity challenges and antitrust counterclaims.
3. Practical Risk Assessment for Patent Holders
Companies pursuing incremental patent improvements must evaluate the litigation and regulatory risk that evergreening strategies create. A company filing multiple continuation applications on a maturing drug or platform technology should consider whether each application claims a genuine advance or merely a cosmetic change. Patent holders who combine evergreening with aggressive enforcement, exclusionary licensing, or reverse-settlement payments face heightened FTC scrutiny. The cost of defending an FTC challenge or antitrust lawsuit often exceeds the value of the marginal patent protection gained.
Key Factors Courts Evaluate
| Factor | Relevance to Evergreening Risk |
| Strength of underlying inventions | Weak or obvious improvements increase antitrust exposure |
| Timing and frequency of filings | Patterns of filings near expiration suggest anticompetitive intent |
| Conduct toward competitors | Aggressive enforcement or sham litigation raises red flags |
| Licensing and settlement practices | Reverse settlements or exclusionary terms invite FTC scrutiny |
| Disclosure to the USPTO | Failure to disclose prior art or related applications may trigger inequitable conduct |
4. Strategic Considerations for Software Patent Law and Technology Companies
Software and technology firms face similar evergreening pressures as pharmaceutical companies, though the regulatory environment differs. Patent thickets in software are common, and competitors often challenge validity through inter partes review (IPR) proceedings at the USPTO Patent Trial and Appeal Board. A company considering a series of related patent filings should conduct a candid assessment of whether each application claims a non-obvious advance or merely a design variation. If the improvements are genuine and the company's licensing practices are reasonable, evergreening poses less regulatory risk. Conversely, if the improvements are marginal and the company combines patent enforcement with exclusionary conduct, litigation and FTC action become likely outcomes.
Before pursuing an aggressive evergreening strategy, evaluate whether the cost of potential antitrust defense and regulatory challenge justifies the incremental market exclusivity gained. Consider whether a narrower patent portfolio combined with trade secret protection, licensing flexibility, and genuine innovation investment would better serve long-term competitive positioning. The evergreening question ultimately turns on whether the patent holder is using valid patents to protect legitimate innovation or using the patent system itself as a barrier to entry.
Local Application of Federal Legal Precedents
Federal court decisions regarding evergreening, particularly those interpreting the Hatch-Waxman Act, significantly inform local enforcement and oversight practices in the District. D.C. .uthorities closely monitor for deceptive marketing, unsupported medical claims, or unfair trade practices that could violate local consumer protection laws. The use of federal court precedent provides D.C. .ith a legal framework to assess the competitive deployment of evergreening strategies in its local healthcare market, with the aim of balancing intellectual property rights and public health and consumer interests.
13 Aug, 2025
